NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01287624,Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC),https://clinicaltrials.gov/study/NCT01287624,TNBC,COMPLETED,"This is a prospective, multi-center, open-labeled, randomized phase III clinical trial comparing overall response rate (ORR), progression free survival (PFS), overall survival (OS) and toxicity obtained with gemcitabine cisplatin combination (GP) versus gemcitabine paclitaxel combination (GT).",NO,Breast Cancer,"DRUG: Gemcitabine,cisplatin|DRUG: Gemcitabine, Paclitaxel","PFS (Progression Free Survival), 6 weeks","Objective Response Rate (ORR), 6 weeks",,Fudan University,307 Hospital of PLA|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Sun Yat-sen University|Tianjin Medical University Cancer Institute and Hospital|Zhejiang Cancer Hospital|Changhai Hospital,FEMALE,"ADULT, OLDER_ADULT",PHASE3,240,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,Fudan BR2010-04|CBCSG 006,2011-01,2014-03,2014-03,2011-02-01,,2015-03-23,"Fudan University Cancer Hospital, Shanghai, Shanghai, 200032, China",
